Literature DB >> 25349003

Recommendations on screening for prostate cancer with the prostate-specific antigen test.

Neil Bell1, Sarah Connor Gorber1, Amanda Shane1, Michel Joffres1, Harminder Singh1, James Dickinson1, Elizabeth Shaw1, Lesley Dunfield1, Marcello Tonelli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25349003      PMCID： PMC4216256          DOI： 10.1503/cmaj.140703

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  48 in total

1.  15-year followup of a population based prostate cancer screening study.

Authors:  Anders Kjellman; Olof Akre; Ulf Norming; Magnus Törnblom; Ove Gustafsson
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

Review 2.  Stop the silent misdiagnosis: patients' preferences matter.

Authors:  Albert G Mulley; Chris Trimble; Glyn Elwyn
Journal:  BMJ       Date:  2012-11-08

3.  Prostate cancer screening: what we know, don't know, and believe.

Authors:  Otis W Brawley
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

4.  Effect of treatment on quality of life among men with clinically localized prostate cancer.

Authors:  M M Schapira; W F Lawrence; D A Katz; T L McAuliffe; A B Nattinger
Journal:  Med Care       Date:  2001-03       Impact factor: 2.983

5.  Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

Authors:  Eva Johansson; Gunnar Steineck; Lars Holmberg; Jan-Erik Johansson; Tommy Nyberg; Mirja Ruutu; Anna Bill-Axelson
Journal:  Lancet Oncol       Date:  2011-08-05       Impact factor: 41.316

6.  Survival associated with treatment vs observation of localized prostate cancer in elderly men.

Authors:  Yu-Ning Wong; Nandita Mitra; Gary Hudes; Russell Localio; J Sanford Schwartz; Fei Wan; Chantal Montagnet; Katrina Armstrong
Journal:  JAMA       Date:  2006-12-13       Impact factor: 56.272

7.  NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.

Authors:  Judd W Moul; Hans Lilja; O John Semmes; Raymond S Lance; Robert L Vessella; Martin Fleisher; Clarisse Mazzola; Mark J Sarno; Barbara Stevens; Robert E Klem; Jonathan E McDermed; Melissa T Triebell; Thomas H Adams
Journal:  Urology       Date:  2012-10-26       Impact factor: 2.649

8.  Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study.

Authors:  Richard M Hoffman; William C Hunt; Frank D Gilliland; Robert A Stephenson; Arnold L Potosky
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

Review 10.  Overdiagnosis and overtreatment of early detected prostate cancer.

Authors:  C H Bangma; S Roemeling; F H Schröder
Journal:  World J Urol       Date:  2007-02-14       Impact factor: 4.226
View more
  84 in total

1.  The utility of provincial AS guidelines.

Authors:  Munir Jamal
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

2.  Prostate cancer screening: going beyond the clinical evidence.

Authors:  Murray Krahn
Journal:  CMAJ       Date:  2014-10-27       Impact factor: 8.262

3.  PSA screening: And now…a message from our experts.

Authors:  Anil Kapoor; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

4.  Making our voices heard.

Authors:  J Stuart Oake
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

5.  [Not Available].

Authors:  Anil Kapoor; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

6.  [Not Available].

Authors:  J Stuart Oake
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

7.  In 2124, half of all men can count on developing prostate cancer.

Authors:  P A Pollock; A Ludgate; R J Wassersug
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

Review 8.  Highlights of the university of toronto urology update 2014.

Authors:  Sender Herschorn
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

9.  Quality of the screening process: An overlooked critical factor and an essential component of shared decision making about screening.

Authors:  James A Dickinson; Roland Grad; Brenda J Wilson; Neil R Bell; Harminder Singh; Olga Szafran; Guylène Thériault
Journal:  Can Fam Physician       Date:  2019-05       Impact factor: 3.275

10. 

Authors:  James A Dickinson; Roland Grad; Brenda J Wilson; Neil R Bell; Harminder Singh; Olga Szafran; Guylène Thériault
Journal:  Can Fam Physician       Date:  2019-05       Impact factor: 3.275
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.